Cara Therapeutics Inc (STU:69C)
€ 0.2602 -0.006 (-2.25%) Market Cap: 14.50 Mil Enterprise Value: -22.28 Mil PE Ratio: 0 PB Ratio: 22.37 GF Score: 33/100

Cara Therapeutics Inc at Canaccord Genuity Growth Conference Transcript

Aug 09, 2023 / 12:00PM GMT
Release Date Price: €2.66 (+2.15%)
Sumant Kulkarni
Canaccord Genuity LLC - Analyst

Good morning, everyone. I'm Sumant Kulkarni, one of the senior biotech analysts here at Canaccord Genuity, and I'm pleased to welcome all of you to our 43rd Annual Growth Conference. I'm very happy to kick it off with Cara Therapeutics here today.

It's very interesting company. They have a product that's out in the market already sold by a partner, and also a product that's in development that has a lot of things going on that we should probably be focusing on here.

I'll turn it over to Chris Posner, the CEO; and then we also have Ryan Maynard, the CFO; and CMO, Jo Goncalves. And in the audience, we have Chief Strategy Officer, Iris Francesconi. So with that, Chris, thanks a lot for making it and thank you, everyone, for tuning in on the webcast as well.

Chris Posner
Cara Therapeutics, Inc. - CEO, President, & Director

Yeah, Sumant. Thanks for having us this morning.

Sumant Kulkarni
Canaccord Genuity LLC - Analyst

So if you want to give a few

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot